Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Revenue (2016 - 2025)

Adma Biologics (ADMA) has disclosed Revenue for 14 consecutive years, with $139.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 18.39% year-over-year to $139.2 million, compared with a TTM value of $510.2 million through Dec 2025, up 19.63%, and an annual FY2025 reading of $510.2 million, up 19.63% over the prior year.
  • Revenue was $139.2 million for Q4 2025 at Adma Biologics, up from $134.2 million in the prior quarter.
  • Across five years, Revenue topped out at $139.2 million in Q4 2025 and bottomed at $8.9 million in Q4 2022.
  • Average Revenue over 5 years is $75.1 million, with a median of $74.5 million recorded in 2022.
  • The sharpest move saw Revenue tumbled 83.84% in 2022, then surged 731.62% in 2023.
  • Year by year, Revenue stood at $55.0 million in 2021, then crashed by 83.84% to $8.9 million in 2022, then skyrocketed by 731.62% to $73.9 million in 2023, then surged by 59.06% to $117.5 million in 2024, then grew by 18.39% to $139.2 million in 2025.
  • Business Quant data shows Revenue for ADMA at $139.2 million in Q4 2025, $134.2 million in Q3 2025, and $122.0 million in Q2 2025.